IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages 281-289

  Shindo, H ^a   Maekawa, S ^a   Komase, K ^a   Miura, M ^a   Kadokura, M ^a   Sueki, R ^a   Komatsu, N ^a   Shindo, K ^a   Amemiya, F ^a   Nakayama, Y ^a   Inoue, T ^a   Sakamoto, M ^a   Yamashita, A ^a   Moriishi, K ^a   Enomoto, N ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

HCV; IFN ; IL 28B; ISG; microarray; synergistic inhibition

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; INTERLEUKIN 28B; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RNA REPLICATION; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; CELL LINE; DRUG SYNERGISM; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MICROARRAY ANALYSIS; VIRUS REPLICATION;

EID: 84875223097     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01649.x     Document Type: Article

References (22)

1. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
2. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
3. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
4. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
5. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345 e1331-1337.
6. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R,. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-131.
7. Kotenko SV, Gallagher G, Baurin VV, et al,. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
8. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
9. Marcello T, Grakoui A, Barba-Spaeth G, et al,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
10. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD,. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008; 283: 30079-30089.
11. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N,. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 2005; 329: 1350-1359.
12. Aoyagi K, Ohue C, Iida K, et al,. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37: 1802-1808.
13. Zhang L, Jilg N, Shao RX, et al,. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011; 55: 289-298.
14. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR,. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
15. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R,. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-7758.
16. Doyle SE, Schreckhise H, Khuu-Duong K, et al,. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906.
17. Maher SG, Sheikh F, Scarzello AJ, et al,. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115.
18. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH,. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo. Hepatology 2011; 53: 1154-1163.
19. Franois-Newton V, de Freitas Almeida GM, Payelle-Brogard B, et al,. USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α Response. PLoS ONE 2011; 6: e22200.
20. Langhans B, Kupfer B, Braunschweiger I, et al,. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865.
21. Urban TJ, Thompson AJ, Bradrick SS, et al,. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
22. Abe H, Hayes CN, Ochi H, et al,. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094-1101.